As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

India's latest health survey reveals significant improvements in maternal care and child vaccination rates. Stunting among children has see...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

India's industrial output for April reached 4.9% under a revised Index of Industrial Production (IIP) series with an updated base year of 2...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...

Government spending on healthcare has surged to Rs 3.85 lakh crore in 2022-23, nearly tripling from a decade ago. This increased public inv...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Indian pharmaceutical exports reached over $31 billion in FY26. March saw a significant 23% drop, primarily due to a slowdown in the United...

In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Vaccination is making a striking difference in Minnesota and keeping the current level of positive cases from becoming an emergency that ov...